Your Guide to EU Representative Requirements for Non-EU AI MedTech

For non-EU developers of AI-enabled medical technology, navigating European representation requirements is a critical and increasingly complex task. The General Data Protection Regulation (GDPR) has long mandated an Article 27 Representative for many non-EU entities processing EU residents' data. Now, the looming EU AI Act introduces a parallel need for an Authorized Representative for companies placing high-risk AI systems on the EU market. This convergence creates a significant challenge and a strategic decision point for manufacturers. The central question is no longer just about appointing a representative, but about selecting a single, competent partner capable of effectively managing the dual responsibilities of data protection and AI product compliance. Choosing a provider requires moving beyond a simple GDPR compliance check and adopting a robust evaluation framework that probes for integrated expertise across legal, regulatory, and technical domains. A future-proof partner must be able to bridge the gap between data privacy and the technical lifecycle management of an AI-powered medical device. ### Key Points * **Dual-Role Representation:** For AI MedTech, appointing a single representative for both GDPR Article 27 and the EU AI Act can streamline compliance and reduce administrative overhead, but this partner must possess deep, integrated expertise. * **Beyond a Mailbox Service:** The role of an EU representative, especially under the AI Act, is not passive. It involves active responsibilities, technical understanding, and significant legal liability. * **Technical Competence is Critical:** A representative for an AI-enabled medical device must have the technical and regulatory competence to understand AI risk management files, post-market surveillance data, and incident reporting obligations under both the AI Act and the EU MDR. * **Clarity in the Mandate:** The service agreement or mandate must explicitly and separately define the provider’s roles and responsibilities under GDPR and the AI Act. Ambiguity can create significant compliance gaps. * **Liability and Insurance are Non-Negotiable:** The AI Act places direct liability on the Authorized Representative. Therefore, verifying their professional indemnity insurance and understanding the contractual allocation of risk is a crucial part of the selection process. * **A True Regulatory Partnership:** The goal is to select a representative who acts as a strategic partner—one who can provide insights, facilitate communication with multiple authorities, and support the product's entire EU lifecycle. ## Understanding the Dual Roles: GDPR Rep vs. AI Act Authorized Rep While both roles involve acting as a point of contact within the EU, their functions, responsibilities, and the authorities they interact with are distinct. For a non-EU AI medical device manufacturer, understanding these differences is the first step toward selecting a qualified partner. ### The GDPR Article 27 Representative The role of the Article 27 Representative is centered entirely on data protection. It was established by the GDPR to ensure that data subjects and supervisory authorities in the EU have a local point of contact for non-EU companies that process their personal data. * **Primary Purpose:** To be the main contact for all issues related to the processing of personal data under GDPR. * **Key Responsibilities:** * Acting as the point of contact for EU data protection authorities (DPAs). * Serving as the contact for data subjects who wish to exercise their rights (e.g., access, rectification, erasure). * Maintaining a copy of the company’s Record of Processing Activities (ROPA) and making it available to authorities upon request. * **Who They Interact With:** Data Protection Authorities (e.g., Ireland's DPC, France's CNIL) and individual data subjects. ### The EU AI Act Authorized Representative The EU AI Act introduces the concept of an Authorized Representative for non-EU providers of high-risk AI systems. This role is focused on product safety, conformity, and market surveillance, mirroring the function of an Authorized Representative under other New Legislative Framework regulations like the Medical Device Regulation (MDR). * **Primary Purpose:** To ensure and verify that a non-EU manufacturer’s high-risk AI system complies with the AI Act before and after it is placed on the market. * **Key Responsibilities:** * Verifying that the EU declaration of conformity and technical documentation have been properly drawn up. * Keeping a copy of the technical documentation and the EU declaration of conformity for review by authorities. * Acting as the point of contact for national market surveillance authorities. * Cooperating with authorities on any action taken to eliminate risks posed by the AI system. * Informing the manufacturer about complaints or reports from individuals about risks related to the AI system. * **Who They Interact With:** National market surveillance authorities and competent authorities responsible for the AI Act. ### Key Overlaps and Differences for AI MedTech | Feature | GDPR Article 27 Representative | AI Act Authorized Representative | | :--- | :--- | :--- | | **Primary Regulation** | General Data Protection Regulation (GDPR) | EU AI Act | | **Main Focus** | Data protection and privacy | AI system safety, conformity, and performance | | **Interacts With** | Data Protection Authorities (DPAs) | Market Surveillance Authorities | | **Core Documentation**| Record of Processing Activities (ROPA) | Technical Documentation, Declaration of Conformity | | **Key Liability** | Liability related to GDPR obligations | Direct liability for placing a non-compliant AI system on the market | For an AI-powered medical device, these two roles are deeply intertwined. The data used to train and test the AI model is often sensitive health data, falling squarely under GDPR. At the same time, the AI model itself is a core component of a medical device subject to the AI Act and MDR. A single event, such as a data breach or a model malfunction causing patient harm, could trigger investigations from both a DPA and a market surveillance authority. A unified representative can manage this complex interplay. ## A Framework for Selecting Your Integrated EU Representative To ensure you select a partner capable of handling this dual mandate, a structured evaluation process is essential. The following framework expands on the key questions every non-EU AI MedTech manufacturer should ask. ### Criterion 1: Unified Expertise and Competence A qualified representative must demonstrate deep, practical knowledge of data protection law, AI technology, and medical device regulations. **What to Look For:** * **A multidisciplinary team:** The provider should have access to Data Protection Officers (DPOs), regulatory affairs specialists with MDR/IVDR experience, and technical experts who understand AI/ML concepts. * **Verifiable experience:** Ask for anonymized case studies or references from other SaMD or MedTech clients. **Checklist of Questions to Ask Potential Providers:** * Can you describe your team's experience with medical device software (MDSW) under Regulation (EU) 2017/745 (MDR)? * How are you preparing for the implementation of the AI Act, and how do you stay current with its evolving requirements? * Please explain how an AI system's risk management file (under the AI Act and ISO 14971) interacts with a Data Protection Impact Assessment (DPIA) required by GDPR. * Who on your team possesses the technical background to review AI model architecture, validation reports, or post-market surveillance plans for algorithmic drift? * How would you handle a request from a market surveillance authority that also contains questions about the personal data used to train the AI model? ### Criterion 2: Scope of Mandate and Service Agreement The contract is the foundation of the relationship. It must be clear, comprehensive, and unambiguous about the provider’s dual roles. **What to Look For:** * **A detailed service agreement, not a one-page letter of appointment.** The agreement should clearly delineate the responsibilities under each regulation. * **Transparent communication protocols and service-level agreements (SLAs).** **Key Contractual Clauses to Scrutinize:** * **Explicit Designation:** The mandate must explicitly state that the entity is being appointed to act as both the GDPR Article 27 Representative and the Authorized Representative under the AI Act. * **Defined Responsibilities:** Look for separate clauses detailing the specific tasks to be performed under each regulation. This avoids confusion and ensures all legal obligations are covered. * **Communication Protocols:** The contract should define the process and timeline for forwarding communications from authorities and data subjects. What happens if a DPA makes a request on a Friday afternoon? * **Documentation Handling:** How will they securely store and manage your technical documentation and ROPA? What are the procedures for providing it to an authority? * **Termination and Transition:** The agreement should outline a clear process for transitioning representation to another provider, including the transfer of all necessary documentation. ### Criterion 3: Technical and Regulatory Acumen for AI SaMD For a complex product like AI-powered SaMD, a representative with only a legal or administrative background is insufficient. They must be able to engage in substantive conversations about your product. **What to Look For:** * **An understanding of the full product lifecycle.** They should be able to discuss requirements from initial design and data collection through post-market monitoring. * **Familiarity with relevant standards,** such as ISO 13485 (Quality Management Systems), ISO 14971 (Risk Management), and emerging AI standards. **Assessment Areas:** * **AI Risk Management:** Can they discuss the unique risks of AI, such as algorithmic bias, data drift, and cybersecurity vulnerabilities, in the context of a medical device risk management framework? * **Post-Market Surveillance (PMS):** Do they understand that PMS for an AI device is not static? It must include ongoing monitoring of the model's performance in the real world. Can they discuss how this data would be collected and reviewed? * **Change Management:** How would they advise on handling significant changes to the AI model that could affect its conformity or data processing activities? ### Criterion 4: Liability, Insurance, and Risk Allocation The AI Act dramatically increases the stakes by imposing direct liability on the Authorized Representative. This makes a thorough review of their liability coverage and contractual terms an essential part of due diligence. **What to Look For:** * **A provider who acknowledges and is prepared for this liability.** Be wary of any provider that downplays these new responsibilities. * **A fair and transparent allocation of risk in the service agreement.** **Due Diligence Checklist:** * **Request a Certificate of Insurance:** Ask for a copy of their current professional indemnity and liability insurance policy. * **Verify Coverage Amount:** Is the coverage level appropriate for a high-risk medical device? A minimum of several million Euros is often expected. * **Review Liability and Indemnification Clauses:** Scrutinize the contract to understand how liability is shared. While the manufacturer retains ultimate responsibility for the product, the contract should not allow the representative to disclaim all responsibility for their own duties. ## Finding and Comparing GDPR Article 27 Representative Providers Selecting the right partner is a strategic sourcing decision that requires a structured process. 1. **Identify Potential Providers:** Start by building a list of potential providers. Look for firms that specialize in both data protection and medical device regulatory affairs. Use professional networks, industry conference exhibitor lists, and specialized service directories. 2. **Issue a Request for Proposal (RFP):** Use the detailed checklists and questions from the framework above to create a formal RFP. This ensures you receive comparable information from each potential provider, allowing for an "apples-to-apples" comparison. 3. **Conduct Due Diligence Interviews:** Shortlist 2-3 providers and schedule interviews with the key personnel who would be managing your account. This is your opportunity to assess their expertise, communication style, and cultural fit. 4. **Review Sample Agreements and Insurance:** Before making a final decision, request a sample service agreement and their certificate of insurance. Have your legal counsel review these documents carefully against the criteria outlined above. Choosing the cheapest option is rarely the best strategy. The potential costs of non-compliance—including fines, product recalls, and reputational damage—far outweigh the cost of a qualified, competent representative. Focus on value, expertise, and a partnership approach. To find qualified vetted providers [click here](https://cruxi.ai/regulatory-directories/gdpr_art27_rep) and request quotes for free. ## Key EU Regulations and References When discussing requirements with potential providers, it is helpful to be familiar with the core legal texts. Manufacturers should always refer to the latest official versions of these documents. * **Regulation (EU) 2016/679 - The General Data Protection Regulation (GDPR):** The primary regulation for data protection in the EU, with Article 27 defining the role of the representative. * **The EU AI Act (Proposal for a Regulation on Artificial Intelligence):** The forthcoming regulation that will establish rules for AI systems, including the role of the Authorized Representative for non-EU providers. * **Regulation (EU) 2017/745 - The Medical Device Regulation (MDR):** The primary regulation for medical devices in the EU, which also defines the role and responsibilities of an Authorized Representative for medical devices. *** This article is for general educational purposes only and is not legal, medical, or regulatory advice. For device-specific questions, sponsors should consult qualified experts and consider engaging FDA via the Q-Submission program. --- *This answer was AI-assisted and reviewed for accuracy by Lo H. Khamis.*